Recent Updates
Recently added Catalysts
MDGL Positive Sentiment

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: Madrigal Pharmaceuticals announced the granting of equity inducement awards to 23 new employees under its 2025 Inducement Plan. The awards include options to purchase 842 shares and 8,296 restricted stock units. These inducements aim to attract and retain talent in the company, with specific vesting schedules outlined.

Market Sentiment Analysis

POSITIVE FACTORS

  • Madrigal granted equity awards to 23 new employees.
  • The awards are part of the 2025 Inducement Plan.
  • Options and restricted stock units align with employee retention.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+125%
120-day peak, hindsight
Typical move
44.9%
average across 7 past catalysts
Lead asset
Resmetirom
Phase 3 · Non-Alcoholic Fatty Liver Disease

Full Press Release Details

CONSHOHOCKEN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2026 and November 14, 2026 to a total of 23 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 842 shares of Madrigal’s common stock, and in the aggregate 8,296 time-based restricted stock units. All options were granted on November 1, 2026 and have an exercise price of $430.36 per share, which is equal to the closing price of the company’s common stock on the grant date. Options vest as follows: (i) 25% of the option shares will vest on the first anniversary of the grant date and (ii) 6.25% of the option shares will vest on each quarterly anniversary following the first anniversary of the grant date. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact Tina Ventura, IR@madrigalpharma.com

Media Contact Christopher Frates, media@madrigalpharma.com

Frequently Asked Questions

What are the inducement awards granted by Madrigal?

Madrigal granted equity awards to 23 new employees as inducements.

How many shares were included in the equity awards?

The awards included options to purchase 842 shares.

What is the vesting schedule for the options?

Options vest 25% after one year and 6.25% quarterly thereafter.

What is Rezdiffra?

Rezdiffra is a medication for treating metabolic dysfunction-associated steatohepatitis.

Last updated: Nov 18, 2026